Skip to main content
. Author manuscript; available in PMC: 2013 Jan 2.
Published in final edited form as: FEBS Lett. 2011 Nov 24;586(1):27–31. doi: 10.1016/j.febslet.2011.11.017

Figure 1.

Figure 1

Treatment of cancer cells with glibenclamide increases gap junction communication. A) Representative images of metastatic C8161.9 donor cells were labeled with Calcein (green) and CM-DiI (red) and co-cultured with non-labeled acceptor cells in the absence or presence of 10µmol/L glibenclamide. Calcein can be visualized spreading from donor cells to acceptor cells. B) Quantification of calcein/DiI assays measuring dye transfer from donor to acceptor cells using flow cytometry in MDA-MB-231, MDA-MB-435 and C8161.9 cancer cell lines. Results are represented as fold change between non-treated (NT) and glibenclamide treated groups measuring the number of acceptor cells receiving calcein per donor cell. (* P < 0.05, error bars represent mean ± standard deviation)